Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial

Topic:

Clinical Trials

Poster Number: 91

Author(s):

Craig McDonald, MD, University of California Davis Health, Shiwen Wu, The Third Medical Center of PLA General Hospital, Beijing, China, Sheffali Gulati, All India Institute of Medical Sciences, New Delhi, India, Hirofumi Komaki, MD, PhD, Translational Medical Center, National Center of Neurology and Psychiatry, Rosa E Escobar-Cedillo, Institudo Nacional de Rehabilitación, Ciudad de Mexico, Anna Kostera-Pruszczyk, MD, PhD, Department of Neurology, Medical University of Warsaw, Warsaw, Poland, Dmitry Vlodavets, PhD MD, Veltischev Clinical Pediatric Research Institute, Moscow, Russia, Jong-Hee Chae, Seoul National University Hospital, Seoul, South Korea, Yuh-Jyh Jong, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan, Peter Karachunski, MD, University of Minnesota, Jeffrey Statland, MD, University of Kansas Medical Center, Michelle Lorentzos, The Children’s Hospital at Westmead, Westmead New South Wales, Australia, Vinay Penematsa, MD, PTC Therapeutics Inc., Connie Chou, PTC Therapeutics Inc., Min Lin, PTC Therapeutics Inc., South Plainfield, NJ, USA, Christian Werner, Dr. med., PTC Therapeutics, Pannie (Panayiota) Trifillis, PhD, PTC Therapeutics, Inc., Greg Gordon, MD, PTC Therapeutics, Matthew Klein, MD, PTC Therapeutics Inc., South Plainfield, NJ, USA

Study 041 (NCT03179631) is an international, phase 3, randomized, double-blind, placebo-controlled 72-week ataluren trial in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) followed by a 72-week open-label period. Here, we describe efficacy and safety results from the placebo-controlled phase.

Boys with nmDMD aged ≥5 years, on corticosteroids, and with a 6-minute walk distance (6MWD) ≥150m were eligible. The primary objective was to determine ataluren’s effect on ambulatory function, assessed by the 6-minute walk test. Boys were randomized 1:1 to ataluren:placebo. The intention-to-treat (ITT) population comprised randomized boys who received ≥1 dose of study treatment. Predefined subgroups included boys with ≥300m 6MWD and ≥5s stand from supine (primary) and those with 300-400m 6MWD.

Ataluren and placebo groups in the ITT population and key subgroups were balanced according to enrolment age, baseline 6MWD, corticosteroid use and time to stand from supine. Significant differences in mean 6MWD change from baseline and rate of change favored ataluren in the ITT population (14.4m; 0.20m/week; p=0.0248) and 300-400m 6MWD subgroup (24.2m; 0.34m/week; p=0.0310), representing a 21% and 30% slowing of the decline rate in 6MWD in these groups, respectively. There were significant treatment benefits in time to 10% worsening of 6MWD. The number of ITT patients who lost ambulation receiving placebo was almost double that of those receiving ataluren. Ataluren was well tolerated, had no probable drug-related serious adverse events (AEs), and AE frequency (85.3%) was similar to placebo (84.7%).

Study 041 confirms ataluren’s favorable risk-benefit as shown in previous clinical and real-world evidence studies.